L01EX03 • pazopanib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Pazopanibum is an alternative name for pazopanib, a medication used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. It acts as a tyrosine kinase inhibitor, blocking the growth of blood vessels supplying tumors and slowing cancer progression.
The medication is taken orally, usually once daily, and should be used as directed by your doctor. Regular check-ups are important to monitor the effectiveness of the treatment and any potential side effects.
Side effects may include nausea, diarrhea, high blood pressure, fatigue, or changes in liver function. In rare cases, severe reactions such as liver failure or bleeding may occur.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of pazopanibum.
Substance: pazopanib
Date of last drug list: 01-06-2025
Commercial code: W70018004
Concentration: 200mg
Pharmaceutical form: tablets
Quantity: 90
Product type: generic
Price: 4276.37 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: REMEDICA LTD. - CIPRU
Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
Number: 15266/2024/04
Shelf life: 3 years